Exela Pharma Sciences Recalls 103,950 Vials of Sodium Bicarbonate Injection Due to Sterility Concerns
Exela Pharma Sciences LLC has initiated a Class II recall of 103,950 vials of 8.4% Sodium Bicarbonate Injection, USP, due to a lack of sterility assurance. This nationwide recall, impacting critical intravenous medication, necessitates immediate action from procurement, supply chain, and regulatory teams to mitigate patient risk and ensure continuity of supply.
FDA Class II Recall: Exela Pharma Sciences' Sodium Bicarbonate Injection Faces Sterility Concerns
Exela Pharma Sciences LLC has initiated a voluntary, firm-initiated Class II recall, identified as D-0303-2025, for its 8.4% Sodium Bicarbonate Injection, USP, 50 mEq/50 mL (1 mEq/mL). This critical intravenous product, supplied in 25 x 50 mL single-dose vials per carton, is being recalled due to a 'Lack of Assurance of Sterility.' The recall specifically impacts two manufacturing lots: 10006417 and 10006418, both carrying an expiration date of November 30, 2026. A substantial quantity of 103,950 vials is affected by this action. For procurement directors and supply chain VPs, this event signals an immediate need to audit existing inventory for these specific lots. A Class II classification indicates that exposure to the violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. However, for an injectable product like Sodium Bicarbonate, used in critical care settings, any compromise in sterility presents a significant patient safety risk. Regulatory affairs heads must ensure rapid compliance with the recall instructions and prepare for potential inquiries regarding product disposition and alternative sourcing strategies. The nationwide distribution pattern means this issue has broad implications across the U.S. healthcare system.
Exela Pharma Sciences' Lenoir Facility: A Key Manufacturer of Injectable Drugs
Exela Pharma Sciences LLC operates its manufacturing facility at 1245 Blowing Rock Blvd, Lenoir, NC 28645-3618, within the United States. This site is responsible for producing human prescription drugs, specifically for intravenous use, including the recalled 8.4% Sodium Bicarbonate Injection, USP. The company serves as a manufacturer for these critical medications, which are distributed nationwide. For business development executives and supply chain VPs, understanding the operational footprint of key suppliers like Exela Pharma Sciences is crucial. This facility's role in the production of essential injectable drugs means any disruption, such as a sterility-related recall, can have cascading effects on the availability of vital medications across the U.S. market. The product's various NDC codes (e.g., 51754-5001-1 for the inner vial, 51754-5001-4 for the carton, and others like 51754-5001-5, 51754-5011-4, 51754-5002-5, 51754-5012-4) indicate its broad packaging and distribution within the pharmaceutical supply chain. This event underscores the importance of geographical and manufacturing diversification in sourcing strategies to mitigate risks associated with single-site production vulnerabilities.
Nationwide Supply Chain Exposure for Sodium Bicarbonate Injection
The recall of Exela Pharma Sciences' Sodium Bicarbonate Injection has a 'Nationwide' distribution pattern, indicating that healthcare providers and pharmacies across the entire United States are potentially impacted. Sodium Bicarbonate is a foundational medication used in various clinical scenarios, including metabolic acidosis, drug intoxications, and as an alkalinizing agent. Its critical nature means that any disruption in its supply can have immediate and severe consequences for patient care. Procurement directors must immediately assess their current stock, identify affected lots (10006417 and 10006418), and initiate quarantine procedures. This recall directly impacts inventory management and necessitates urgent re-sourcing efforts. Supply chain VPs face the challenge of rapidly identifying and qualifying alternative suppliers to prevent stockouts and ensure continuity of patient treatment. Business development executives should note the market gap created by this recall, which may present opportunities for alternative manufacturers to expand their market share. Regulatory affairs heads must manage the communication with healthcare facilities regarding the recall and ensure all regulatory requirements for product return and replacement are met efficiently. The sheer volume of 103,950 vials underscores the significant logistical and clinical challenge this recall presents.
Strategic Sourcing: Identifying Alternative Sodium Bicarbonate Suppliers
Given the critical nature of 8.4% Sodium Bicarbonate Injection, USP, and the nationwide impact of this recall, procurement teams must swiftly identify and qualify alternative suppliers. The ChemLifeIntel Knowledge Graph does not currently list specific alternative manufacturers for Sodium Bicarbonate Injection. This absence highlights the potential for market concentration and the inherent risks associated with relying on a limited supplier base for essential medications. Procurement directors should initiate an immediate market scan to identify other FDA-approved manufacturers of Sodium Bicarbonate Injection. Key considerations for evaluation include manufacturing capacity, lead times, quality track record, and regulatory compliance history. Expedited qualification processes will be essential, but without compromising due diligence on quality management systems and sterility assurance protocols. Supply chain VPs should also explore opportunities for geographic diversification of their supplier base to build resilience against future localized disruptions. This proactive approach is vital to safeguard against potential future supply shortages and maintain uninterrupted patient care, transforming a reactive recall response into a strategic supply chain enhancement.
Broader Industry Context: Persistent Sterility Assurance Challenges
While the ChemLifeIntel Knowledge Graph does not contain specific prior regulatory actions or Warning Letters directly linked to Exela Pharma Sciences LLC, this recall concerning 'Lack of Assurance of Sterility' is not an isolated incident within the broader pharmaceutical industry. Recent parallel events, such as the FDA Class II Recall of Essential Wellness Pharma's Progesterone Injection due to similar sterility assurance failures in June 2026, underscore a persistent challenge across the sector. For regulatory affairs heads and quality assurance leaders, this pattern signals a systemic vulnerability in manufacturing processes for sterile injectable products. It emphasizes the critical need for robust environmental monitoring, aseptic processing controls, and comprehensive quality management systems across all suppliers. Business development executives should recognize that companies demonstrating superior quality and compliance in sterile manufacturing can gain a significant competitive advantage. Procurement directors must integrate a thorough review of sterility assurance data and audit findings into their supplier qualification and ongoing monitoring processes, moving beyond basic compliance checks to a proactive risk assessment framework that anticipates and mitigates such widespread industry issues.
Remediation Pathways and Future Regulatory Scrutiny for Exela Pharma Sciences
The recall of Exela Pharma Sciences' Sodium Bicarbonate Injection is currently designated as 'Ongoing' by the FDA, indicating that the firm's corrective actions and the agency's oversight are still in progress. As a firm-initiated voluntary recall, Exela Pharma Sciences LLC would have notified the FDA via letter, outlining the issue and its proposed actions. The immediate expectation from the FDA is a comprehensive investigation into the root cause of the 'Lack of Assurance of Sterility,' followed by the implementation of robust Corrective and Preventive Actions (CAPA). For regulatory affairs heads, monitoring Exela's remediation progress is critical. This typically involves a detailed assessment of manufacturing processes, environmental controls, personnel training, and quality control procedures. Future FDA inspections are highly probable to verify the effectiveness of these CAPA measures. For procurement directors and supply chain VPs, this means that while Exela works to resolve the issue, the reliability of future supply from their Lenoir, NC facility remains under scrutiny. Diversifying the supplier base for critical products like Sodium Bicarbonate Injection is a prudent strategy to mitigate potential long-term supply risks and ensure business continuity, irrespective of the outcome of Exela's remediation efforts. This event serves as a reminder that regulatory compliance is an ongoing commitment, with significant commercial implications.